Vaccination does prevent infection. Does it prevent it 100% of the time, no. Would she still have gotten COVID had she been vaccinated, maybe, maybe no.
It's a number I pulled from Trump's butt just to illustrate a point. Heck, it felt like half of the nation's trusted him more than the CDC. https://www.politico.com/news/2020/04/01/trump-coronavirus-millions-saved-160814
Another reason to hate John Stockton...he's as much of a stooge as the anti-vaxxers in here... Stockton Says Athletes are Dropping Dead Thank god we got Kareem talking sense.
The BA.2 variant appears to be a sub variant of Omicron. There also is a BA.1 variant out there too. It's possible the BA.2 variant might not be easy to test for under current tests but also that the current vaccines will still prevent severe illness from them. https://www.newsweek.com/stealth-omicron-covid-subvariant-how-many-countries-40-1672104 Stealth Omicron COVID Variant BA.2 That May Spread Faster Found in at Least 40 Countries BY ED BROWNE ON 1/24/22 AT 6:58 AM EST he Omicron BA.2 sub-variant, also dubbed "stealth Omicron," has been detected in at least 40 countries worldwide. BA.2 has caught attention in recent days as it has been responsible for an increasing proportion of Omicron infections compared to the BA.1 lineage that has been the dominant Omicron type so far. Labs in countries including Denmark and Norway have reported that the sub-variant has been gaining ground, accounting for nearly half of all COVID cases in the former as of January 20, marking a sharp increase in recent weeks. Virologists say that there is much to learn about BA.2, but it appears the sub-variant may have a transmission advantage over BA.1. In a press release issued last Friday, the U.K.'s Health Security Agency (HSA) said that BA.2 had been classified as a variant under investigation (VUI) due to international and domestic cases, adding that BA.2 appears to have an increased growth rate compared to BA.1, based on early analysis. However, the HSA stated that the proportion of BA.2 cases in the country compared to BA.1 was "currently low" and that further analysis was needed to determine the significance of the sub-variant and its mutations. "So far, there is insufficient evidence to determine whether BA.2 causes more severe illness than Omicron BA.1, but data is limited and UKHSA continues to investigate," said Dr Meera Chand, COVID-19 Incident Director at the HSA. Effectiveness of Vaccines A press release from Denmark's Statens Serum Institut (SSI) infectious disease research institution last week stated that it is expected that vaccines will continue to have an effect on severe illness caused by BA.2 A total of 40 countries had uploaded BA.2 sequences to the virus sequencing database GISAID since November 17, the HSA said last Friday. Outbreak.info, an online tool that presents COVID statistics using GISAID data, put that figure at 49 as of Monday. One notable aspect of BA.2 is that it lacks a genetic characteristic that scientists had used to identify Omicron cases previously—giving credence to its "stealth Omicron" monicker. However, Cornelius Roemer, a computational biologist at the University of Basel in Switzerland, tweeted last week that BA.2 is still detectable on PCR tests and branded news reports to the contrary as "totally wrong." "Depending on the PCR test used it may not look like BA.1 (the other Omicron). But it will still give a positive result," he wrote. According to GISAID on Monday morning, a total of 12,842 BA.2 sequences had been uploaded to its database from around the world. Some 67 of those were reported from the USA.
That article is from April 1, 2020, which Covid was still in its infancy. So that's the initial estimates you were referring to. But where was anyone saying that "at end of the year"?
Hopefully the judge correctly understands vaccination does help prevent infection. We know that it is a fact that it does help in prevention. It isn't a guarantee, but it decreases the odds of infections. That's one reason why vaccinations are so awesome.
It's insignificant if it all. Places that are ultravaxed/masked like Israel have record cases. meanwhile
lol it's poorly phrased with me posting a modeled number then claiming if they ran the assumption and I quote again "(not that current models say it will)" You're free to invalidate It on a literal basis. I could've used the original op/ed's example to make the same figurative point. If i had some Adderall in me, maybe I'd start a slick podcast on wtf really happened to Deborah Blix, the WH's model maven. I'm not pulling hairs or keeping score for everytime modelers are wrong or F-F-F-FAUCI!!! is wrong. That wasn't my agenda either. I just consume a lot of news and hate it when i get an upset stomach every other week.
https://www.nytimes.com/2021/12/21/health/covid-monoclonal-antibodies-omicron.html https://www.nytimes.com/2021/11/30/...tion=click&module=RelatedLinks&pgtype=Article
Meanwhile, the two treatments have been proven ineffective... but who would you believe, scientists or some guy working for a trump political strategy company? Lab tests: Eli Lilly, Regeneron antibody therapies lose out against Omicron https://www.reuters.com/business/he...herapies-lose-out-against-omicron-2021-12-14/
Was just about to respond with that. For those who can't get behind the pay wall. Hospitals Scramble as Antibody Treatments Fail Against Omicron The single remaining monoclonal antibody therapy effective against the variant is now in short supply in the U.S., imperiling an option that doctors and hospitals have relied on. By Christina Jewett, Carl Zimmer and Rebecca Robbins Published Dec. 21, 2021Updated Dec. 23, 2021 Hospitals, drug companies and Biden administration officials are racing to address one of the Omicron variant’s biggest threats: Two of the three monoclonal antibody treatments that doctors have depended on to keep Covid-19 patients from becoming seriously ill do not appear to thwart the latest version of the coronavirus. The one such treatment that is still likely to work against Omicron is now so scarce that many doctors and hospitals have already run through their supplies. Monoclonal antibodies have become a mainstay of Covid treatment, shown to be highly effective in keeping high-risk patients from being hospitalized. But even as infections surge and Omicron becomes the dominant form of new cases in the United States, some hospitals have begun scaling back the treatments, fearing they have become suddenly useless. In New York, hospital administrators at NewYork-Presbyterian, N.Y.U. Langone and Mount Sinai all said in recent days that they would stop giving patients the two most commonly used antibody treatments, made by Eli Lilly and Regeneron, according to memos obtained by The Times and officials at the health systems. “This is a dramatic change just in the last week or so,” said Dr. Daniel Griffin, an infectious disease specialist at Columbia University in New York. “And I think it makes sense.” The Omicron variant accounted for an estimated 73 percent of new cases in the United States last week, according to the Centers for Disease Control and Prevention. That’s up from just over 12 percent the week before. The one monoclonal antibody treatment that has performed well against Omicron in laboratory experiments is also the most recently authorized: sotrovimab, made by GlaxoSmithKline and Vir Biotechnology and cleared in May. Already in high demand even before Omicron arose, the supply of sotrovimab is very limited for now. But the situation is likely to improve somewhat in the coming weeks. The Biden administration is in talks with GlaxoSmithKline about securing more doses to be delivered by early next year, the administration official said. Regulators are also expected this week to authorize antiviral pills from Pfizer and Merck, the first two products in a new class of Covid treatments, according to two senior administration officials. Both pills can stave off severe illness in the high-risk patients that until now might have received antibody treatments. Pfizer’s treatment, known as Paxlovid, is especially promising, as it has been found to be highly effective — and likely to work against Omicron. Supplies of these antivirals will be limited at first, but even modest amounts may help ease the strain on doctors who had been relying until now on monoclonal antibodies to treat Covid patients.
